Baird Maintains Outperform on Castle Biosciences, Maintains $34 Price Target
$CSTL
Medical Specialities
Health Care
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and maintains $34 price target.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/14/2023 | $25.00 | Buy | Guggenheim |
| 1/5/2023 | $54.00 | Sector Outperform | Scotiabank |
| 1/7/2022 | $59.00 | Overweight | Stephens & Co. |
| 11/9/2021 | $85.00 → $75.00 | Outperform | SVB Leerink |
| 7/14/2021 | $80.00 → $85.00 | Outperform | SVB Leerink |
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024, at 10:50 a.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available following the conclusion of the live broadcast. About Castle Biosciences Castle Biosciences (NASDAQ:CSTL) is a leading diagnostics company improving healt
Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and Professional Development Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been named a Houston Top Workplace for 2024 by the Houston Chronicle. This is the fourth consecutive year the Company has been ranked among the Houston metro area's top workplaces. Castle also earned three Culture Excellence awards in the areas of Employee Appreciation, Employee Well-Being and Professional Development. "Achieving a Houston Top Workplace honor for the f
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will share new data highlighting the clinical performance of its DecisionDx-Melanoma and MyPath Melanoma tests at the American Society of Dermatopathology (ASDP) 61st Annual Meeting, being held Nov. 7-10, in Chicago. "At Castle, we focus strongly on continued evidence development to demonstrate where our tests might be able to add value to clinical decision-making," said Rebecca Critchley-Thorne, Ph.D., vice president of research and development at Castle Biosciences. "Our data to be presented at ASDP support the ability of our tests to provide accurate risk-stratification i
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00
Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00
Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00
144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
10-Q - CASTLE BIOSCIENCES INC (0001447362) (Filer)
8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit
-Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in
SAN DIEGO, May 26, 2021 /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. Cassava Sciences Inc (NASDAQ:SAVA) On July 1, Cassava Sciences engaged the U.S. Department of Justice (DOJ) and the U.S. Secu
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family reasons, effective July 5, 2024. NIO shares dipped 8.5% to $4.4550 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Qualigen Therapeutics, Inc. (NASDAQ:QLGN) jumped 120% to $0.3870 after gaining 6% on Wednesday. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) rose 70.5% to $4.65 after gaining around 14% on Wednesday. MediWound Ltd. (NASDAQ:MDWD) shares jumped 45.6% to $21.12 after dipping around 7% on Wednesday. Koss Corporation (NASDAQ:KOSS) shares climb
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and maintains $34 price target.
Q3 2024 revenue increased 39% over Q3 2023 to $86 million Q3 2024 total test reports increased 41% over Q3 2023 Raising full-year 2024 revenue guidance to $320-330 million from $275-300 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2024. "We are thrilled with our third quarter performance, which reflects the continued success of our growth initiatives and the dedication of our team," said Derek Maetzold, president and chief executive officer of Castle Biosciences.
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2024, after the close of market on Monday, Nov. 4, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/435529710, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.as
Q2 2024 revenue increased 74% over Q2 2023 to $87 million Q2 2024 total test reports increased 49% over Q2 2023 Raising full-year 2024 revenue guidance to $275-300 million from $255-265 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2024. "We achieved another quarter of exceptional performance, thanks to the hard work of our talented team and strength of our innovative test portfolio," said Derek Maetzold, president and chief executive officer of Castle Biosciences.